Segall Bryant & Hamill LLC Buys New Stake in Kenvue Inc. (NYSE:KVUE)

Segall Bryant & Hamill LLC bought a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,288 shares of the company’s stock, valued at approximately $516,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of KVUE. O Shaughnessy Asset Management LLC increased its stake in Kenvue by 34.3% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 30,765 shares of the company’s stock valued at $660,000 after purchasing an additional 7,854 shares in the last quarter. Axxcess Wealth Management LLC acquired a new position in Kenvue during the 1st quarter valued at approximately $255,000. Advisors Asset Management Inc. acquired a new position in Kenvue during the 1st quarter valued at approximately $206,000. Mount Yale Investment Advisors LLC increased its stake in Kenvue by 154.8% during the 1st quarter. Mount Yale Investment Advisors LLC now owns 27,754 shares of the company’s stock valued at $596,000 after purchasing an additional 16,862 shares in the last quarter. Finally, SVB Wealth LLC increased its stake in Kenvue by 7.3% during the 1st quarter. SVB Wealth LLC now owns 14,042 shares of the company’s stock valued at $301,000 after purchasing an additional 952 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $24.08 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The company has a market capitalization of $46.17 billion, a PE ratio of 43.78, a price-to-earnings-growth ratio of 2.19 and a beta of 1.36. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.31. The company’s fifty day moving average price is $22.84 and its 200 day moving average price is $20.86.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The business had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company’s revenue was down .4% compared to the same quarter last year. During the same period last year, the firm posted $0.31 earnings per share. On average, research analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.41%. The ex-dividend date is Wednesday, November 13th. Kenvue’s payout ratio is 149.09%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. increased their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Jefferies Financial Group assumed coverage on shares of Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price objective on the stock. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. UBS Group increased their price objective on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Finally, Bank of America increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.